You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
This Podcast features an interview with Carla Rothlin and Sourav Ghosh, senior authors of a Research Article that appears in the 12 August 2014 issue of Science Signaling, about a potential target for the treatment of glioblastoma. Glioblastomas are brain tumors, and most are characterized by increased activity of the epidermal growth factor receptor (EGFR). Drugs that inhibit EGFR signaling have shown limited success in treating these tumors, suggesting that additional oncogenic signaling pathways need to be identified in order to effectively treat patients. Kusne et al. found that atypical protein kinase C (aPKC) was activated in glioblastoma cells by EGFR signaling and by the proinflammatory cytokine tumor necrosis factor–α (TNF-α), which is present in the tumor microenvironment. Inhibiting aPKC reduced the growth of glioblastomas in mice, suggesting that targeting aPKC may be an effective strategy for treating glioblastoma.
